Study identifier:D419CR00026
ClinicalTrials.gov identifier:NCT05557838
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-label, Multi-center Phase IIIb Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Phase 3
No
Durvalumab, Tremelimumab
All
210
Interventional
18 Years - n/a
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jun 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: cohort 1 durvalumab in combination with tremelimumab | Drug: Durvalumab Durvalumab IV (intravenous infusion) Other Name: MEDI4736 Drug: Tremelimumab Tremelimumab IV (intravenous infusion) |
Experimental: cohort 2 durvalumab in combination with tremelimumab | Drug: Durvalumab Durvalumab IV (intravenous infusion) Other Name: MEDI4736 Drug: Tremelimumab Tremelimumab IV (intravenous infusion) |